Clinical Trials
16 trialsNCT03480971 2024-11-20
Treatment of Radiation and Cisplatin Induced Toxicities with Tempol
Matrix Biomed, Inc.
Phase 2 Recruiting
NCT05966194 2024-11-15
KEVLARx
EpicentRx, Inc.
Phase 2 Recruiting
NCT03515538 2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2 Completed
NCT04046250 2023-08-25
TK112690
Tosk, Inc.
Phase 2 Completed
NCT05658016 2023-08-14
Phase 2a Study to Evaluate Suppression of Radiotherapy-induced Mucositis by TK112690
Tosk, Inc.
Phase 2 Unknown
NCT05669521 2023-08-14
Phase 2a Study to Evaluate Suppression of 5-Fluorouracil -Induced Mucositis by TK112690
Tosk, Inc.
Phase 2 Unknown
NCT02606994 2019-02-06
TPvsM
Oral Defense, LLC
Phase 2 Terminated
NCT02324335 2019-01-16
Brilacidin
Innovation Pharmaceuticals, Inc.
Phase 2 Completed
NCT02885376 2018-12-21
Study of Dentoxol® Mouthrinse for Oral Mucositis
Ingalfarma SpA
Phase 2 Completed
NCT01554254 2016-08-31
Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation
Tarix Pharmaceuticals
Phase 2 Withdrawn
NCT01882374 2016-08-31
Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation
Tarix Pharmaceuticals
Phase 2 Withdrawn
NCT01882387 2016-08-31
Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
Tarix Pharmaceuticals
Phase 2 Withdrawn
NCT01247246 2014-05-26
Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer
SciClone Pharmaceuticals
Phase 2 Unknown
NCT00727324 2012-04-02
Safety/Efficacy Study of Bovine Intestinal Alkaline Phosphatase in Patients With Moderate to Severe Ulcerative Colitis
AM-Pharma
Phase 2 Completed
NCT01083875 2010-03-18
Study to Determine the Effects Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region
Access Pharmaceuticals, Inc.
Phase 2 Completed
NCT00230191 2007-01-15
Safety and Efficacy of RK0202 in Oral Mucositis
RxKinetix
Phase 2 Completed